• Consensus Rating: Buy
  • Consensus Price Target: $239.50
  • Forecasted Upside: 18.65 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$201.86
▲ +7.29 (3.75%)

This chart shows the closing price for BGNE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BeiGene Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BGNE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BGNE

Analyst Price Target is $239.50
▲ +18.65% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for BeiGene in the last 3 months. The average price target is $239.50, with a high forecast of $296.00 and a low forecast of $210.00. The average price target represents a 18.65% upside from the last price of $201.86.

This chart shows the closing price for BGNE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in BeiGene. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
6/11/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
9/9/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/8/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/8/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/6/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/4/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/3/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/3/2022

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/15/2022GuggenheimBoost Target$210.00N/A
11/10/2022CowenBoost Target$200.00 ➝ $213.00Low
11/10/2022SVB LeerinkBoost TargetOutperform$200.00 ➝ $210.00Low
11/10/2022CowenBoost Target$200.00 ➝ $213.00Low
10/13/2022Morgan StanleyBoost TargetOverweight$290.00 ➝ $295.00Low
10/13/2022GuggenheimUpgradeNeutral ➝ Buy$205.00Low
10/12/2022SVB LeerinkUpgradeMarket Perform ➝ Outperform$177.00 ➝ $200.00Low
8/9/2022JPMorgan Chase & Co.Reiterated RatingOverweight$296.00Low
7/15/2022Morgan StanleyLower TargetOverweight$300.00 ➝ $293.00Low
4/12/2022Morgan StanleyBoost TargetOverweight$330.00 ➝ $338.00High
3/17/2022SVB LeerinkDowngradeOutperform ➝ Market Perform$300.00 ➝ $177.00Low
2/28/2022Morgan StanleyLower TargetOverweight$360.00 ➝ $330.00Medium
2/28/2022SVB LeerinkLower TargetOutperform$334.00 ➝ $300.00Medium
2/7/2022Deutsche Bank AktiengesellschaftInitiated CoverageBuyMedium
1/18/2022Morgan StanleyLower TargetOverweight$407.00 ➝ $360.00Low
1/13/2022JPMorgan Chase & Co.Initiated CoverageOverweightMedium
10/14/2021SVB LeerinkLower TargetOutperform$417.00 ➝ $414.00Low
10/12/2021Sanford C. BernsteinInitiated CoverageOutperform$431.00Low
10/6/2021CLSAUpgradeUnderperform ➝ BuyLow
8/16/2021Morgan StanleyLower TargetOverweight$409.00 ➝ $407.00Low
6/14/2021SVB LeerinkBoost TargetPositive ➝ Outperform$388.00 ➝ $417.00Low
6/3/2021Morgan StanleyBoost TargetOverweight$357.00 ➝ $409.00Low
5/10/2021Morgan StanleyLower TargetOverweight$375.00 ➝ $357.00Medium
3/16/2021HSBCBoost TargetBuy$296.00 ➝ $385.00Low
3/1/2021CLSADowngradeOutperform ➝ Underperform$330.00 ➝ $321.00Low
2/18/2021CowenBoost TargetOutperform$348.00 ➝ $429.00High
1/19/2021Morgan StanleyBoost TargetOverweight$310.00 ➝ $375.00Low
1/12/2021Piper SandlerBoost Target$185.00 ➝ $190.00High
12/8/2020LADENBURG THALM/SH SHUpgradeNeutral ➝ Buy$278.00Low
11/19/2020SVB LeerinkBoost TargetOutperform$240.00 ➝ $327.00Medium
11/11/2020Morgan StanleyBoost TargetOverweight$270.00 ➝ $310.00Low
11/9/2020LADENBURG THALM/SH SHDowngradeBuy ➝ NeutralHigh
11/6/2020Maxim GroupDowngradeBuy ➝ HoldMedium
11/6/2020SVB LeerinkBoost TargetOutperform$210.00 ➝ $240.00High
11/6/2020Piper SandlerDowngradeNeutral ➝ Underweight$175.00 ➝ $185.00High
10/13/2020Morgan StanleyBoost TargetOverweight$241.00 ➝ $270.00High
8/10/2020Morgan StanleyBoost TargetOverweight$235.00 ➝ $241.00High
8/7/2020LADENBURG THALM/SH SHBoost TargetBuy$232.00 ➝ $268.00Medium
8/6/2020Piper SandlerBoost TargetNeutral$165.00 ➝ $175.00Medium
7/15/2020Morgan StanleyBoost TargetOverweight$190.00 ➝ $235.00Medium
7/10/2020Maxim GroupReiterated RatingPositive ➝ Buy$190.00 ➝ $250.00High
6/3/2020SVB LeerinkBoost TargetOutperform$207.00 ➝ $210.00Low
5/28/2020Morgan StanleyBoost TargetOverweight$184.00 ➝ $190.00Low
4/15/2020Morgan StanleyLower TargetOverweight$210.00 ➝ $184.00High
3/13/2020MacquarieUpgradeUnderperform ➝ NeutralHigh
3/3/2020Maxim GroupLower TargetPositive ➝ Buy$210.00 ➝ $190.00High
3/3/2020CowenReiterated RatingBuy$200.00High
2/18/2020The Goldman Sachs GroupInitiated CoverageBuy$197.30Low
1/27/2020CowenReiterated RatingOutperformMedium
1/17/2020Morgan StanleyInitiated CoverageOverweight$210.00Low
12/16/2019CowenReiterated RatingBuy$216.00Medium
12/16/2019Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$165.00High
12/16/2019GuggenheimDowngradeBuy ➝ NeutralHigh
12/10/2019Maxim GroupReiterated RatingBuy$210.00Low
11/19/2019UBS GroupDowngradeBuy ➝ NeutralHigh
11/18/2019Bank of AmericaReiterated RatingBuy$230.00Low
11/15/2019Piper Jaffray CompaniesReiterated RatingBuy$200.00 ➝ $230.00High
11/15/2019GuggenheimReiterated RatingBuy$205.00 ➝ $228.00High
11/14/2019Maxim GroupReiterated RatingBuy$210.00Low
11/13/2019CowenBoost TargetOutperform$170.00 ➝ $225.00Low
11/4/2019JPMorgan Chase & Co.Set TargetBuy$162.00 ➝ $215.00Low
11/4/2019Maxim GroupBoost TargetBuy$170.00 ➝ $210.00Low
11/1/2019GuggenheimSet TargetBuy$205.00Low
11/1/2019Piper Jaffray CompaniesBoost Target$180.00 ➝ $200.00Low
10/16/2019CowenReiterated RatingBuy$170.00High
10/11/2019Morgan StanleyLower TargetOverweight$201.00 ➝ $200.00Low
8/12/2019Morgan StanleyLower TargetOverweight$207.00 ➝ $201.00Medium
8/9/2019Maxim GroupSet TargetBuy$170.00Low
7/15/2019Morgan StanleyLower TargetOverweight$210.00 ➝ $207.00Low
7/5/2019MacquarieInitiated CoverageUnderperformMedium
6/20/2019Piper Jaffray CompaniesReiterated RatingBuyLow
6/4/2019Sanford C. BernsteinInitiated CoverageOutperform ➝ Outperform$201.00Medium
5/31/2019Maxim GroupSet TargetBuy$170.00Low
5/31/2019CowenReiterated RatingBuy$170.00Low
5/14/2019Morgan StanleyBoost TargetOverweight$200.00 ➝ $210.00High
5/9/2019Piper Jaffray CompaniesBoost TargetPositive ➝ Overweight$180.00High
3/15/2019Bank of AmericaInitiated CoverageBuy ➝ Buy$200.00Medium
2/28/2019Maxim GroupSet TargetBuy$170.00High
2/28/2019Piper Jaffray CompaniesLower TargetOverweight$170.00Low
1/3/2019Maxim GroupReiterated RatingBuy$170.00High
12/17/2018Maxim GroupReiterated RatingBuy$170.00Low
12/3/2018Maxim GroupSet TargetBuy$170.00High
12/2/2018Piper Jaffray CompaniesSet TargetBuy$200.00High
11/28/2018JPMorgan Chase & Co.Initiated CoverageOverweight$174.00Medium
11/27/2018Maxim GroupSet TargetBuy$170.00Medium
11/20/2018JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$174.00High
11/15/2018Maxim GroupSet TargetBuy$170.00Low
11/7/2018Piper Jaffray CompaniesSet TargetBuy$200.00N/A
11/7/2018CowenReiterated RatingBuyMedium
10/14/2018CowenReiterated RatingBuyLow
9/24/2018SVB LeerinkInitiated CoverageOutperform ➝ Outperform$215.00Medium
9/20/2018CowenReiterated RatingBuyLow
9/20/2018Maxim GroupReiterated RatingBuy$215.00Low
9/19/2018CLSAInitiated CoverageBuy$160.75Low
9/17/2018GuggenheimInitiated CoverageBuyLow
8/10/2018CowenReiterated RatingBuyLow
7/30/2018Maxim GroupReiterated RatingBuy$225.00Medium
7/23/2018Piper Jaffray CompaniesSet TargetBuy$200.00Low
6/15/2018CowenReiterated RatingBuyLow
5/18/2018Maxim GroupBoost TargetBuy$200.00 ➝ $225.00Low
5/14/2018Credit Suisse GroupInitiated CoverageOutperform ➝ OutperformHigh
5/10/2018Maxim GroupSet TargetBuy$200.00High
4/16/2018Maxim GroupSet TargetBuy$200.00Low
4/13/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$200.00Medium
4/10/2018Maxim GroupBoost TargetBuy ➝ Buy$160.00 ➝ $200.00Low
3/21/2018Morgan StanleyBoost TargetOverweight ➝ Overweight$93.00 ➝ $200.00High
3/1/2018Robert W. BairdReiterated RatingHold$138.00High
3/1/2018LADENBURG THALM/SH SHReiterated RatingBuy$172.00Medium
3/1/2018Maxim GroupReiterated RatingBuy ➝ Buy$144.00 ➝ $160.00Medium
2/7/2018Maxim GroupReiterated RatingBuyLow
1/22/2018Maxim GroupSet TargetBuy$120.00Medium
1/8/2018CowenReiterated RatingBuyHigh
1/3/2018Maxim GroupSet TargetBuy$120.00Low
12/18/2017Maxim GroupSet TargetBuy$120.00Low
12/11/2017CowenReiterated RatingBuyLow
12/11/2017Maxim GroupSet TargetBuy$120.00Low
(Data available from 12/4/2017 forward)

News Sentiment Rating

0.68 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 18 very positive mentions
  • 15 positive mentions
  • 7 negative mentions
  • 1 very negative mentions
5/8/2022
  • 4 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
6/7/2022
  • 13 very positive mentions
  • 16 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
7/7/2022
  • 6 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 3 very negative mentions
8/6/2022
  • 4 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 3 very negative mentions
9/5/2022
  • 8 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
10/5/2022
  • 17 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 6 very negative mentions
11/4/2022
  • 5 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
12/4/2022

Current Sentiment

  • 5 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
BeiGene logo
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $201.86
Low: $193.16
High: $207.18

50 Day Range

MA: $168.99
Low: $125.51
High: $207.71

52 Week Range

Now: $201.86
Low: $118.18
High: $350.95

Volume

325,081 shs

Average Volume

256,835 shs

Market Capitalization

$20.96 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86

Frequently Asked Questions

What sell-side analysts currently cover shares of BeiGene?

The following Wall Street sell-side analysts have issued reports on BeiGene in the last year: Cowen Inc, Cowen Inc., Deutsche Bank Aktiengesellschaft, Guggenheim, JPMorgan Chase & Co., Morgan Stanley, StockNews.com, and SVB Leerink LLC.
View the latest analyst ratings for BGNE.

What is the current price target for BeiGene?

6 Wall Street analysts have set twelve-month price targets for BeiGene in the last year. Their average twelve-month price target is $239.50, suggesting a possible upside of 18.6%. JPMorgan Chase & Co. has the highest price target set, predicting BGNE will reach $296.00 in the next twelve months. Guggenheim has the lowest price target set, forecasting a price of $210.00 for BeiGene in the next year.
View the latest price targets for BGNE.

What is the current consensus analyst rating for BeiGene?

BeiGene currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BGNE will outperform the market and that investors should add to their positions of BeiGene.
View the latest ratings for BGNE.

What other companies compete with BeiGene?

How do I contact BeiGene's investor relations team?

BeiGene's physical mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The company's listed phone number is 861085148500 and its investor relations email address is [email protected] The official website for BeiGene is www.beigene.com. Learn More about contacing BeiGene investor relations.